Advertisement
The activity of two genes may help predict certain breast cancer patients' odds of survival and guide their treatment

F12, STC2 Genes May Help Predict Breast Cancer Survival

0
Tracking DNA activity patterns may someday help women with HER2+ breast cancers
Residents frequently order perceived unnecessary inpatient laboratory tests

Residents Often Order Perceived Unnecessary Lab Tests

0
Behaviors attributed to health system culture, lack of transparency about health care service costs
The longer a woman is overweight

Duration of Adult Obesity Affects Cancer Risk in Women

0
Researchers find odds for four types of cancer rise significantly for every decade of obesity
Financial incentives may boost smoking cessation rates

More Evidence Paying Smokers to Quit May Work

0
But cost may be $28,000 to get one additional smoker to succeed long term
New surgery guidelines for treatment of women with ductal carcinoma in situ who undergo breast-conserving surgery with whole breast radiation could reduce both unnecessary surgeries and recurrence rates

New Guidelines Set Safe Surgery Margins for DCIS

0
2 mm is enough to guard against recurrences while reducing need for additional surgeries
Female doctors in the United States make much less than their male colleagues

U.S. Female Doctors Reimbursed Significantly Less Than Males

0
Medicare reimbursement review finds male specialists earning more
Female oncologists report more grief responses to patient death

Female Oncologists Report More Grief Responses, Burnout

0
For both genders, grief reactions linked to emotional distress among those at high levels of burnout
For women with surgically staged IA or IB endometrial adenocarcinoma

Vaginal Brachytherapy Cuts Mortality in Early Uterine Cancer

0
Reduction in mortality for stage IA and IB disease; radiotherapy underused in this population
Cancer has overtaken cardiovascular disease as the leading cause of death in 12 European countries

Cancer Now Leading Cause of Death in Some European Nations

0
Gains against cardiovascular disease, especially in Western Europe, likely behind the shift
In patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or untreated AML unfit for intensive chemotherapy

Venetoclax Monotherapy Active in AML With Adverse Features

0
Overall response rate 19%; additional 19% have antileukemic activity without meeting IWG criteria